Griguolo, GaiaBrasó Maristany, FaraGonzález Farré, BlancaPascual, TomásChic Ruché, NúriaSaurí, TamaraKates, RonaldGluz, OlegMartínez, DéboraParé, LaiaTsvetkova, VassilenaPesantez, DavidVidal Losada, Maria JesúsAdamo, BarbaraMuñoz Mateu, MontserratGalván, PatriciaBarberá, LauraCuatrecasas Freixas, MiriamChristgen, MathiasKreipe, HansMonge Escartín, InésVillagrasa, PatriciaSoy Muner, DolorsGiarratano, TommasoDieci, Maria VittoriaConte, PierfrancoHarbeck, NadiaGuarneri, ValentinaPrat Aparicio, Aleix2021-02-242021-02-242020-07-142072-6694https://hdl.handle.net/2445/174260Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA.We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed para n-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally,15 p.application/pdfengcc-by (c) Griguolo, Gaia et al., 2020http://creativecommons.org/licenses/by/3.0/esCàncer de mamaReceptors d'hormonesBreast cancerHormone receptorsinfo:eu-repo/semantics/article7047642021-02-24info:eu-repo/semantics/openAccess32674482